Concepts (221)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Neisseria meningitidis | 8 | 2023 | 36 | 2.780 |
Why?
|
| Meningococcal Infections | 5 | 2022 | 24 | 2.330 |
Why?
|
| Pneumococcal Infections | 19 | 2024 | 299 | 2.310 |
Why?
|
| Pneumococcal Vaccines | 16 | 2024 | 278 | 1.670 |
Why?
|
| Streptococcus pneumoniae | 19 | 2024 | 336 | 1.520 |
Why?
|
| von Willebrand Factor | 3 | 2021 | 21 | 1.210 |
Why?
|
| Meningitis, Bacterial | 3 | 2024 | 38 | 1.080 |
Why?
|
| South Africa | 40 | 2025 | 7596 | 1.050 |
Why?
|
| HIV Infections | 17 | 2024 | 5097 | 1.040 |
Why?
|
| Humans | 51 | 2025 | 14537 | 0.990 |
Why?
|
| Meningitis, Pneumococcal | 3 | 2022 | 20 | 0.970 |
Why?
|
| Influenza, Human | 4 | 2022 | 374 | 0.970 |
Why?
|
| Communicable Diseases | 3 | 2024 | 62 | 0.940 |
Why?
|
| Meningococcal Vaccines | 3 | 2022 | 12 | 0.940 |
Why?
|
| Meningitis | 2 | 2022 | 26 | 0.920 |
Why?
|
| Amphotericin B | 2 | 2016 | 10 | 0.900 |
Why?
|
| Meningitis, Cryptococcal | 3 | 2023 | 16 | 0.900 |
Why?
|
| Serogroup | 13 | 2025 | 150 | 0.880 |
Why?
|
| Meningitis, Meningococcal | 3 | 2022 | 17 | 0.880 |
Why?
|
| Sepsis | 2 | 2022 | 102 | 0.860 |
Why?
|
| Purpura, Thrombotic Thrombocytopenic | 2 | 2021 | 8 | 0.770 |
Why?
|
| Infant | 24 | 2025 | 2244 | 0.740 |
Why?
|
| Perinatal Death | 1 | 2022 | 33 | 0.730 |
Why?
|
| Child, Preschool | 21 | 2025 | 1748 | 0.720 |
Why?
|
| Male | 28 | 2025 | 6754 | 0.710 |
Why?
|
| Female | 30 | 2025 | 9103 | 0.710 |
Why?
|
| AIDS-Related Opportunistic Infections | 4 | 2023 | 195 | 0.690 |
Why?
|
| Cryptococcosis | 3 | 2022 | 17 | 0.670 |
Why?
|
| Vaccines, Conjugate | 7 | 2024 | 171 | 0.650 |
Why?
|
| Adolescent | 18 | 2025 | 2985 | 0.640 |
Why?
|
| Coinfection | 3 | 2019 | 276 | 0.640 |
Why?
|
| Antifungal Agents | 5 | 2023 | 40 | 0.630 |
Why?
|
| Infant, Newborn | 16 | 2025 | 1479 | 0.620 |
Why?
|
| Plasminogen | 1 | 2018 | 1 | 0.600 |
Why?
|
| ADAMTS13 Protein | 1 | 2018 | 8 | 0.600 |
Why?
|
| Child | 17 | 2025 | 2242 | 0.600 |
Why?
|
| Bacteriophages | 1 | 2018 | 4 | 0.580 |
Why?
|
| von Willebrand Diseases | 1 | 2018 | 8 | 0.570 |
Why?
|
| Anti-Bacterial Agents | 8 | 2025 | 293 | 0.570 |
Why?
|
| Incidence | 12 | 2024 | 685 | 0.540 |
Why?
|
| Population Surveillance | 5 | 2021 | 325 | 0.530 |
Why?
|
| Deoxycholic Acid | 1 | 2016 | 2 | 0.510 |
Why?
|
| Influenza Vaccines | 3 | 2021 | 144 | 0.460 |
Why?
|
| Acquired Immunodeficiency Syndrome | 2 | 2014 | 187 | 0.440 |
Why?
|
| Adult | 18 | 2025 | 5913 | 0.440 |
Why?
|
| Aged | 10 | 2025 | 1740 | 0.430 |
Why?
|
| Vaccination | 8 | 2023 | 365 | 0.420 |
Why?
|
| Hospital Mortality | 4 | 2023 | 95 | 0.410 |
Why?
|
| Risk Factors | 11 | 2024 | 1475 | 0.400 |
Why?
|
| Middle Aged | 12 | 2025 | 3601 | 0.400 |
Why?
|
| Cryptococcus gattii | 1 | 2012 | 2 | 0.400 |
Why?
|
| Young Adult | 11 | 2025 | 2498 | 0.380 |
Why?
|
| Prevalence | 5 | 2021 | 1192 | 0.380 |
Why?
|
| Bacterial Infections | 2 | 2023 | 54 | 0.370 |
Why?
|
| Microbial Sensitivity Tests | 5 | 2025 | 198 | 0.360 |
Why?
|
| Streptococcus agalactiae | 3 | 2025 | 202 | 0.350 |
Why?
|
| Hospitalization | 3 | 2024 | 418 | 0.310 |
Why?
|
| Carrier State | 2 | 2021 | 92 | 0.310 |
Why?
|
| Streptococcal Infections | 2 | 2025 | 184 | 0.300 |
Why?
|
| Haemophilus influenzae | 3 | 2023 | 42 | 0.280 |
Why?
|
| Papio ursinus | 2 | 2023 | 3 | 0.260 |
Why?
|
| Drug Resistance, Bacterial | 4 | 2025 | 135 | 0.260 |
Why?
|
| Spike Glycoprotein, Coronavirus | 2 | 2024 | 101 | 0.250 |
Why?
|
| Cross-Sectional Studies | 5 | 2022 | 1422 | 0.230 |
Why?
|
| Sentinel Surveillance | 2 | 2024 | 115 | 0.220 |
Why?
|
| Laboratories | 1 | 2024 | 47 | 0.220 |
Why?
|
| Evolution, Molecular | 1 | 2024 | 60 | 0.220 |
Why?
|
| Bacteremia | 3 | 2015 | 79 | 0.220 |
Why?
|
| Pregnancy Complications, Infectious | 2 | 2021 | 529 | 0.220 |
Why?
|
| Hemostatics | 1 | 2023 | 17 | 0.210 |
Why?
|
| Fungemia | 1 | 2023 | 2 | 0.200 |
Why?
|
| Cryptococcus | 1 | 2023 | 10 | 0.200 |
Why?
|
| Disease Progression | 1 | 2022 | 154 | 0.190 |
Why?
|
| Respiratory Tract Infections | 2 | 2024 | 266 | 0.190 |
Why?
|
| Seasons | 1 | 2022 | 154 | 0.180 |
Why?
|
| Universities | 1 | 2021 | 34 | 0.170 |
Why?
|
| CD4 Lymphocyte Count | 3 | 2024 | 656 | 0.170 |
Why?
|
| Multivariate Analysis | 3 | 2016 | 171 | 0.170 |
Why?
|
| Cytokines | 1 | 2021 | 107 | 0.170 |
Why?
|
| Immune Evasion | 1 | 2021 | 31 | 0.170 |
Why?
|
| Students | 1 | 2021 | 50 | 0.170 |
Why?
|
| Neutralization Tests | 1 | 2021 | 108 | 0.170 |
Why?
|
| Biomarkers | 1 | 2021 | 327 | 0.160 |
Why?
|
| Premature Birth | 1 | 2021 | 80 | 0.160 |
Why?
|
| Hirudins | 1 | 1999 | 1 | 0.160 |
Why?
|
| Respiratory Syncytial Virus, Human | 1 | 2021 | 155 | 0.150 |
Why?
|
| Fibrinolytic Agents | 1 | 1999 | 7 | 0.150 |
Why?
|
| Deamino Arginine Vasopressin | 1 | 2018 | 1 | 0.150 |
Why?
|
| Yeasts | 1 | 2018 | 3 | 0.150 |
Why?
|
| Respiratory Syncytial Virus Infections | 1 | 2021 | 200 | 0.140 |
Why?
|
| Cost-Benefit Analysis | 1 | 2020 | 253 | 0.140 |
Why?
|
| Blood Coagulation Tests | 1 | 2018 | 24 | 0.140 |
Why?
|
| Papio | 3 | 2023 | 28 | 0.140 |
Why?
|
| Retrospective Studies | 2 | 2021 | 799 | 0.140 |
Why?
|
| Genes, Bacterial | 1 | 2017 | 23 | 0.130 |
Why?
|
| Bacterial Capsules | 1 | 2017 | 33 | 0.130 |
Why?
|
| Pandemics | 3 | 2024 | 296 | 0.130 |
Why?
|
| Genetic Variation | 2 | 2024 | 175 | 0.130 |
Why?
|
| Animals | 4 | 2023 | 1081 | 0.130 |
Why?
|
| Treatment Outcome | 3 | 2017 | 889 | 0.130 |
Why?
|
| Drug Combinations | 1 | 2016 | 42 | 0.130 |
Why?
|
| Epidemiological Monitoring | 1 | 2016 | 45 | 0.120 |
Why?
|
| Immunocompromised Host | 2 | 2012 | 34 | 0.120 |
Why?
|
| Statistics as Topic | 1 | 2015 | 31 | 0.120 |
Why?
|
| Prospective Studies | 2 | 2021 | 1160 | 0.110 |
Why?
|
| Ceftriaxone | 1 | 2014 | 13 | 0.110 |
Why?
|
| Mycoses | 1 | 2014 | 8 | 0.110 |
Why?
|
| Mortality | 3 | 2021 | 104 | 0.110 |
Why?
|
| Klebsiella pneumoniae | 2 | 2024 | 39 | 0.100 |
Why?
|
| Age of Onset | 1 | 2012 | 32 | 0.100 |
Why?
|
| Length of Stay | 1 | 2012 | 43 | 0.100 |
Why?
|
| Sex Distribution | 1 | 2012 | 89 | 0.100 |
Why?
|
| Age Distribution | 1 | 2012 | 107 | 0.100 |
Why?
|
| Dysentery, Bacillary | 1 | 2012 | 3 | 0.100 |
Why?
|
| Tyrosine | 1 | 2012 | 2 | 0.090 |
Why?
|
| Immunoglobulin Fab Fragments | 1 | 2012 | 4 | 0.090 |
Why?
|
| Cohort Studies | 2 | 2024 | 967 | 0.090 |
Why?
|
| Thrombosis | 1 | 2012 | 47 | 0.090 |
Why?
|
| Anticoagulants | 1 | 2012 | 57 | 0.090 |
Why?
|
| Serotyping | 2 | 2025 | 66 | 0.090 |
Why?
|
| Cryptococcus neoformans | 1 | 2010 | 1 | 0.090 |
Why?
|
| Age Factors | 3 | 2018 | 370 | 0.090 |
Why?
|
| Antibodies, Monoclonal | 1 | 2012 | 142 | 0.090 |
Why?
|
| Phylogeny | 2 | 2024 | 231 | 0.080 |
Why?
|
| Penicillins | 2 | 2024 | 25 | 0.080 |
Why?
|
| Heptavalent Pneumococcal Conjugate Vaccine | 2 | 2024 | 42 | 0.080 |
Why?
|
| Pregnancy | 3 | 2021 | 1862 | 0.080 |
Why?
|
| Case-Control Studies | 3 | 2017 | 480 | 0.080 |
Why?
|
| Ofloxacin | 1 | 2008 | 4 | 0.070 |
Why?
|
| Public Health Surveillance | 2 | 2021 | 52 | 0.070 |
Why?
|
| Levofloxacin | 1 | 2008 | 21 | 0.070 |
Why?
|
| Genotype | 2 | 2025 | 442 | 0.070 |
Why?
|
| Odds Ratio | 2 | 2017 | 133 | 0.060 |
Why?
|
| Tuberculosis, Multidrug-Resistant | 1 | 2008 | 226 | 0.060 |
Why?
|
| Molecular Epidemiology | 1 | 2025 | 47 | 0.060 |
Why?
|
| Antitubercular Agents | 1 | 2008 | 322 | 0.060 |
Why?
|
| Aged, 80 and over | 2 | 2020 | 468 | 0.060 |
Why?
|
| Whole Genome Sequencing | 1 | 2025 | 44 | 0.060 |
Why?
|
| Microbiology | 1 | 2024 | 1 | 0.060 |
Why?
|
| Erythromycin | 1 | 2024 | 12 | 0.060 |
Why?
|
| Genome, Bacterial | 1 | 2024 | 32 | 0.060 |
Why?
|
| Acinetobacter baumannii | 1 | 2024 | 11 | 0.060 |
Why?
|
| High-Throughput Nucleotide Sequencing | 1 | 2024 | 48 | 0.060 |
Why?
|
| Haemophilus Vaccines | 1 | 2024 | 41 | 0.050 |
Why?
|
| Genome, Viral | 1 | 2024 | 64 | 0.050 |
Why?
|
| Thrombin | 1 | 2023 | 8 | 0.050 |
Why?
|
| ABO Blood-Group System | 1 | 2023 | 5 | 0.050 |
Why?
|
| Public Health | 1 | 2024 | 124 | 0.050 |
Why?
|
| Sequence Analysis, DNA | 2 | 2017 | 181 | 0.050 |
Why?
|
| Alleles | 2 | 2017 | 143 | 0.050 |
Why?
|
| Antigens, Fungal | 1 | 2023 | 9 | 0.050 |
Why?
|
| Mutation | 1 | 2024 | 306 | 0.050 |
Why?
|
| Gram-Positive Bacteria | 1 | 2022 | 9 | 0.050 |
Why?
|
| Gram-Negative Bacteria | 1 | 2022 | 15 | 0.050 |
Why?
|
| Flucytosine | 1 | 2022 | 4 | 0.050 |
Why?
|
| Fluconazole | 1 | 2022 | 17 | 0.050 |
Why?
|
| Inflammation Mediators | 1 | 2021 | 22 | 0.050 |
Why?
|
| Public Health Practice | 1 | 2021 | 7 | 0.040 |
Why?
|
| Streptokinase | 1 | 2021 | 1 | 0.040 |
Why?
|
| Interrupted Time Series Analysis | 1 | 2021 | 21 | 0.040 |
Why?
|
| Blood Donors | 1 | 2021 | 19 | 0.040 |
Why?
|
| Prognosis | 1 | 2021 | 199 | 0.040 |
Why?
|
| Pregnant Women | 1 | 2021 | 89 | 0.040 |
Why?
|
| Mice | 1 | 2021 | 135 | 0.040 |
Why?
|
| Immunization Programs | 1 | 2021 | 81 | 0.040 |
Why?
|
| Quality-Adjusted Life Years | 1 | 2020 | 34 | 0.040 |
Why?
|
| Immunization | 1 | 2020 | 63 | 0.040 |
Why?
|
| Iodine Radioisotopes | 1 | 1999 | 3 | 0.040 |
Why?
|
| Partial Thromboplastin Time | 1 | 1999 | 13 | 0.040 |
Why?
|
| Immunohistochemistry | 1 | 1999 | 26 | 0.040 |
Why?
|
| Half-Life | 1 | 1999 | 22 | 0.040 |
Why?
|
| Recombinant Proteins | 1 | 1999 | 73 | 0.040 |
Why?
|
| Kidney | 1 | 1999 | 46 | 0.040 |
Why?
|
| Antibodies, Viral | 1 | 2021 | 284 | 0.040 |
Why?
|
| Observational Studies as Topic | 1 | 2018 | 21 | 0.040 |
Why?
|
| Disease Outbreaks | 1 | 2018 | 111 | 0.040 |
Why?
|
| Global Health | 1 | 2018 | 193 | 0.030 |
Why?
|
| Empyema | 1 | 2017 | 2 | 0.030 |
Why?
|
| Molecular Sequence Annotation | 1 | 2017 | 4 | 0.030 |
Why?
|
| Genetic Markers | 1 | 2017 | 11 | 0.030 |
Why?
|
| Adhesins, Bacterial | 1 | 2017 | 12 | 0.030 |
Why?
|
| Bacterial Outer Membrane Proteins | 1 | 2017 | 5 | 0.030 |
Why?
|
| Virulence | 1 | 2017 | 25 | 0.030 |
Why?
|
| Genetic Loci | 1 | 2017 | 11 | 0.030 |
Why?
|
| Diabetes Complications | 1 | 2017 | 15 | 0.030 |
Why?
|
| Bronchiectasis | 1 | 2017 | 11 | 0.030 |
Why?
|
| Antigens, Bacterial | 1 | 2017 | 32 | 0.030 |
Why?
|
| Carrier Proteins | 1 | 2017 | 23 | 0.030 |
Why?
|
| Base Sequence | 1 | 2017 | 149 | 0.030 |
Why?
|
| Phenotype | 1 | 2017 | 158 | 0.030 |
Why?
|
| Live Birth | 1 | 2016 | 5 | 0.030 |
Why?
|
| Smoking | 1 | 2017 | 100 | 0.030 |
Why?
|
| Severity of Illness Index | 1 | 2017 | 253 | 0.030 |
Why?
|
| Logistic Models | 1 | 2017 | 254 | 0.030 |
Why?
|
| Bacterial Proteins | 1 | 2017 | 119 | 0.030 |
Why?
|
| Spatio-Temporal Analysis | 1 | 2016 | 14 | 0.030 |
Why?
|
| History, 21st Century | 1 | 2016 | 42 | 0.030 |
Why?
|
| Polymorphism, Single Nucleotide | 1 | 2017 | 198 | 0.030 |
Why?
|
| Streptococcal Vaccines | 1 | 2016 | 47 | 0.030 |
Why?
|
| Demography | 1 | 2015 | 105 | 0.030 |
Why?
|
| Diabetes Mellitus | 1 | 2017 | 146 | 0.030 |
Why?
|
| Penicillin Resistance | 1 | 2014 | 17 | 0.030 |
Why?
|
| Regression Analysis | 1 | 2015 | 133 | 0.030 |
Why?
|
| Seroepidemiologic Studies | 1 | 2015 | 109 | 0.030 |
Why?
|
| Health Status | 1 | 2015 | 111 | 0.030 |
Why?
|
| Time Factors | 1 | 2015 | 507 | 0.030 |
Why?
|
| Socioeconomic Factors | 1 | 2015 | 411 | 0.020 |
Why?
|
| Shigella | 1 | 2012 | 2 | 0.020 |
Why?
|
| Primates | 1 | 2012 | 2 | 0.020 |
Why?
|
| Disease Models, Animal | 1 | 2012 | 45 | 0.020 |
Why?
|
| Tuberculosis | 1 | 2017 | 543 | 0.020 |
Why?
|
| Ploidies | 1 | 2010 | 2 | 0.020 |
Why?
|
| DNA, Fungal | 1 | 2010 | 3 | 0.020 |
Why?
|
| Mycological Typing Techniques | 1 | 2010 | 2 | 0.020 |
Why?
|
| Genes, Mating Type, Fungal | 1 | 2010 | 2 | 0.020 |
Why?
|
| Multilocus Sequence Typing | 1 | 2010 | 19 | 0.020 |
Why?
|
| Molecular Sequence Data | 1 | 2010 | 263 | 0.020 |
Why?
|
| Statistics, Nonparametric | 1 | 2008 | 38 | 0.020 |
Why?
|
| Cross Infection | 1 | 2008 | 52 | 0.020 |
Why?
|
| World Health Organization | 1 | 2008 | 137 | 0.020 |
Why?
|
| Rifampin | 1 | 2008 | 197 | 0.020 |
Why?
|